TY - JOUR
T1 - Impact of Small Valve Size on 1-Year Outcomes After Transcatheter Aortic Valve Implantation in Women (from the WIN-TAVI Registry)
AU - Pivato, Carlo A.
AU - Cao, Davide
AU - Spirito, Alessandro
AU - Sartori, Samantha
AU - Nicolas, Johny
AU - Chiarito, Mauro
AU - Snyder, Clayton
AU - Mehilli, Julinda
AU - Lefèvre, Thierry
AU - Stefanini, Giulio G.
AU - Presbitero, Patrizia
AU - Capranzano, Piera
AU - Tchetche, Didier
AU - Iadanza, Alessandro
AU - Vogel, Birgit
AU - Sardella, Gennaro
AU - Van Mieghem, Nicolas M.
AU - Nardin, Matteo
AU - Tavenier, Anne H.
AU - Meliga, Emanuele
AU - Dumonteil, Nicholas
AU - Fraccaro, Chiara
AU - Trabattoni, Daniela
AU - Mikhail, Ghada
AU - Sharma, Samin
AU - Ferrer, Maria Cruz
AU - Naber, Christoph
AU - Kievit, Peter
AU - Baber, Usman
AU - Petronio, Anna S.
AU - Morice, Marie C.
AU - Chieffo, Alaide
AU - Dangas, George
AU - Mehran, Roxana
N1 - Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/6/1
Y1 - 2022/6/1
N2 - Although most patients with small aortic annulus are women, there is paucity of data on the prognostic impact of small aortic prosthesis in women who underwent transcatheter aortic valve implantation (TAVI). Therefore, we aimed to evaluate the impact of small valve size on 1-year clinical outcomes after TAVI in women. The Women's INternational Transcatheter Aortic Valve Implantation is an all-women registry evaluating patients with severe aortic stenosis who underwent TAVI. Based on the size of the aortic bioprosthesis implanted, women were stratified into small (≤23 mm) and nonsmall (>23 mm) valve. The primary efficacy endpoint was the Valve Academic Research Consortium-2 composite of all-cause death, stroke, myocardial infarction, hospitalization for valve-related symptoms or heart failure or valve-related dysfunction at 1-year follow-up. Of 934 women who underwent TAVI, 388 (41.5%) received a small valve. Women with a small valve size had a lower body mass index, lower surgical risk scores, were less likely to suffer from atrial fibrillation, less often required postdilation and had a lower rate of residual aortic regurgitation grade ≥2. The occurrence of the Valve Academic Research Consortium-2 efficacy endpoint was similar between women treated with small and nonsmall valve (16.0% vs 16.3%, p = 0.881; adjusted hazard ratio 1.34, 95% confidence interval 0.90 to 2.00). Likewise, there were no significant differences in the occurrence of other secondary endpoints after multivariable adjustment. In conclusion, women with severe aortic stenosis who underwent TAVI with the implantation of a small valve bioprosthesis had similar 1-year outcomes as those receiving a nonsmall bioprosthesis.
AB - Although most patients with small aortic annulus are women, there is paucity of data on the prognostic impact of small aortic prosthesis in women who underwent transcatheter aortic valve implantation (TAVI). Therefore, we aimed to evaluate the impact of small valve size on 1-year clinical outcomes after TAVI in women. The Women's INternational Transcatheter Aortic Valve Implantation is an all-women registry evaluating patients with severe aortic stenosis who underwent TAVI. Based on the size of the aortic bioprosthesis implanted, women were stratified into small (≤23 mm) and nonsmall (>23 mm) valve. The primary efficacy endpoint was the Valve Academic Research Consortium-2 composite of all-cause death, stroke, myocardial infarction, hospitalization for valve-related symptoms or heart failure or valve-related dysfunction at 1-year follow-up. Of 934 women who underwent TAVI, 388 (41.5%) received a small valve. Women with a small valve size had a lower body mass index, lower surgical risk scores, were less likely to suffer from atrial fibrillation, less often required postdilation and had a lower rate of residual aortic regurgitation grade ≥2. The occurrence of the Valve Academic Research Consortium-2 efficacy endpoint was similar between women treated with small and nonsmall valve (16.0% vs 16.3%, p = 0.881; adjusted hazard ratio 1.34, 95% confidence interval 0.90 to 2.00). Likewise, there were no significant differences in the occurrence of other secondary endpoints after multivariable adjustment. In conclusion, women with severe aortic stenosis who underwent TAVI with the implantation of a small valve bioprosthesis had similar 1-year outcomes as those receiving a nonsmall bioprosthesis.
UR - http://www.scopus.com/inward/record.url?scp=85130242076&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2022.02.025
DO - 10.1016/j.amjcard.2022.02.025
M3 - Article
C2 - 35461697
AN - SCOPUS:85130242076
SN - 0002-9149
VL - 172
SP - 73
EP - 80
JO - American Journal of Cardiology
JF - American Journal of Cardiology
ER -